The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.
 
Liv Cecilie Vestrheim Thomsen
Consulting or Advisory Role - Eisai
Travel, Accommodations, Expenses - AstraZeneca
 
Alfred Honoré
No Relationships to Disclose
 
Bjorn T. Gjertsen
Leadership - Alden Cancer Therapy II; Kinn Therapeutics
Stock and Other Ownership Interests - Alden Cancer Therapy II; Aprea Therapeutics; BerGenBio; Immunicum; Kinn Therapeutics
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BerGenBio; Jazz Pharmaceuticals; MSD; Novartis; Pfizer; Seagen
Speakers' Bureau - Genzyme; Novartis; Oslo Cancer Cluster; Pfizer
Research Funding - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Alden Cancer Therapy II patent application in relation to CryoIT trial.
Travel, Accommodations, Expenses - AROG; Astellas Pharma; Novartis; Seagen
 
Astrid Børretzen
No Relationships to Disclose
 
Lars Anders Reisæter
No Relationships to Disclose
 
Bjarte Almås
No Relationships to Disclose
 
Svein Inge Helle
No Relationships to Disclose
 
Kristina Førde
No Relationships to Disclose
 
Martin Biermann
No Relationships to Disclose
 
Waqas Azeem
No Relationships to Disclose
 
Benjamin Gabriel
Research Funding - Norwegian Cancer Society
 
Stian Knappskog
No Relationships to Disclose
 
Ole Johan Halvorsen
No Relationships to Disclose
 
Lars Akslen
No Relationships to Disclose
 
Klaus Pantel
Honoraria - Abcam; Agena Bioscience; Atheneum; Beiersdorf; CureVac; DeciBio; Galderma; Hello Healthcare; Hummingbird; Illumina; Impulze; Inflection Biosciences; Ipsen; Medac; Menarini Silicon Biosystems; Merck KGaA; Molecular Health; MSD; Novartis; Roche; Sanofi; Tactics
Consulting or Advisory Role - Agena Bioscience; Hummingbird Diagnostics; Menarini Silicon Biosystems; Sanofi
Research Funding - Cancer-ID (Inst); Janssen Diagnostics
Patents, Royalties, Other Intellectual Property - 10004180.5; 17157020.3 - 1405; 7825055.2; 95108760.7; WO2016 128125A1
Travel, Accommodations, Expenses - Agena Bioscience
 
Sabine Riethdorf
No Relationships to Disclose
 
Anne Margrete Øyan
Stock and Other Ownership Interests - Alden Cancer Therapy II; Alden Cancer Therapy II (I)
 
Karl-Henning Kalland
Stock and Other Ownership Interests - Alden Cancer Therapy II; Alden Cancer Therapy II (I)
Research Funding - Norwegian Cancer Society
Patents, Royalties, Other Intellectual Property - PCT/EP2017/077698 pending
 
Christian Beisland
Honoraria - Pfizer
Consulting or Advisory Role - BMS Norway; MSD
Travel, Accommodations, Expenses - Olympus